Novartis Leadership In Psoriasis Therapies Could Be Consolidated With New Drug "Cosentyx"

The pharma giant Novartis is looking to consolidate its hold on the lead role for new therapies for psoriasis with some remarkable data suggesting the drug could act as a disease modifier for a significant group of patients.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.